Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- Check7 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing v3.6.2, indicating a newer version of the site's software. This update appears to be a backend/platform revision rather than a change to the study details.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page shows a new revision tag v3.6.2, replacing the previous v3.6.0. This indicates a small update to page metadata.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedNew help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment heading was standardized. Recruitment status now indicates No longer looking for participants, and the page revision was updated to v3.6.0.SummaryDifference0.1%

- Check35 days agoChange DetectedNew site at St. Luke's Hospital Of Kansas City in Missouri has been added and the study's total locations updated to 247. Tom Hare is now listed as Study Director, and Rebecca Taub, MD is no longer listed.SummaryDifference0.2%

- Check50 days agoChange DetectedA new footer revision tag 'Revision: v3.5.4' has been added, replacing 'Revision: v3.5.3'. This indicates an update to the page's revision history.SummaryDifference0.0%

- Check57 days agoChange DetectedNew trial sites were added in Roma, Milano, Palermo, Novara, Messina and Brussels Capital in Belgium, along with Budapest. Some previously listed locations were removed or reformatted (e.g., Brussels, Belgium; Messina, Italy; Novara, Italy) to reflect updated site naming.SummaryDifference0.9%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.